Stroke Prevention by ORal Thrombin Inhibition V "SPORTIF V"


Phase N/A Results


A total of 88 primary events were recorded. The primary event rate with ximelagatran was 1.6% per year and with warfarin was 1.2% per year (P=.13). Composite end point of stroke, systemic embolism, myocardial infarction, or death occurred in 119 patients taking warfarin (4.3% per year) and 110 taking ximelagatran (4.2% per year; P = .84). There was no difference between groups in rates of major bleeding, but total bleeding (major and minor) was lower with ximelagatran (37% vs 47% per year; P<.001).